[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJ40e9DbTWq3lsj9T3wQw1W5e6wn6saqbc_dLiUL8xy0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":55,"rows":62},"Blueprint Medicines Corporation",[4],31,false,7,2,5057,3,6,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Indolent Systemic Mastocytosis",4,{"name":18,"count":16},"Carcinoma, Non-Small-Cell Lung",{"name":20,"count":16},"Respiratory Tract Neoplasms",{"name":22,"count":16},"Neoplasms",{"name":24,"count":16},"Neoplasms by Site",{"name":26,"count":16},"Lung Diseases",{"name":28,"count":16},"Carcinoma, Bronchogenic",{"name":30,"count":16},"Carcinoma",[32,37,42,46,50],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06931405","Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","2026-12-31","BLU-808",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03731260","(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis","2027-06-23","Avapritinib",{"nctId":43,"briefTitle":44,"date":45,"intervention":41},"NCT06748001","Avapritinib Rollover Study","2027-12-31",{"nctId":47,"briefTitle":48,"date":49,"intervention":41},"NCT07255638","A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany","2028-12-01",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04910685","(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","2032-09-30","Elenestinib",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,201,234,275,293,381,407,437,459,477,495,521,539,565,583,601,619,637,655,681,699],{"intervention":41,"totalTrials":64,"cells":65},12,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":113,"PHASE3":147,"PHASE4":160,"NA":178},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[71,87,101],{"nctId":72,"briefTitle":73,"status":74,"phases":75,"primaryCompletion":76,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":85},"NCT04908176","A Drug-drug Interaction Study of Avapritinib and Midazolam","COMPLETED",[57],"2024-03-01","2024-05-10","2022-08-24",10,[81,82,83,84],"Gastrointestinal Stromal Tumors","GIST","Non-resectable Advanced Solid Tumors","Recurrent or Unresectable Central Nervous System (CNS) Tumors",[41,86],"midazolam",{"nctId":88,"briefTitle":89,"status":74,"phases":90,"primaryCompletion":91,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":100},"NCT02561988","(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies",[57],"2022-10-05","2023-01-19","2016-03-10",86,[96,97,98,99],"Aggressive Systemic Mastocytosis","Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease","Mast Cell Leukemia","Relapsed or Refractory Myeloid Malignancies",[41],{"nctId":102,"briefTitle":103,"status":74,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":112},"NCT02508532","(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors",[57],"2020-03-06","2021-06-03","2015-08",250,[110,111],"Gastrointestinal Stromal Tumors (GIST)","Other Relapsed or Refractory Solid Tumors",[41],{"trials":114,"activeCount":146,"soonestReadout":40},[115,128,139],{"nctId":116,"briefTitle":117,"status":74,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":126},"NCT04773782","A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling",[57,58],"2025-11-21","2022-02-24",29,[123,124,125],"Solid Tumor, Unspecified, Child","Relapsed Solid Neoplasm","CNS Tumor",[127],"avapritinib",{"nctId":129,"briefTitle":130,"status":74,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":138},"NCT03580655","(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis",[58],"2024-12-18","2018-11-21",107,[136,96,137,98],"Advanced Systemic Mastocytosis","Systemic Mastocytosis With an Associated Hematologic Neoplasm",[41],{"nctId":38,"briefTitle":39,"status":140,"phases":141,"primaryCompletion":40,"completion":40,"start":142,"enrollment":143,"conditions":144,"interventions":145},"ACTIVE_NOT_RECRUITING",[58],"2019-04-16",251,[15],[41],1,{"trials":148,"activeCount":68},[149],{"nctId":150,"briefTitle":151,"status":74,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT03465722","(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST",[59],"2020-03-09","2021-09-15","2018-03-26",476,[82],[127,159],"regorafenib",{"trials":161,"activeCount":146,"soonestReadout":45},[162,170],{"nctId":163,"briefTitle":164,"status":74,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":9,"conditions":168,"interventions":169},"NCT04825574","Study for Patients Previously Treated in Avapritinib Clinical Trials",[60],"2023-11-23","2021-05-21",[81],[41],{"nctId":43,"briefTitle":44,"status":171,"phases":172,"primaryCompletion":45,"completion":45,"start":173,"enrollment":174,"conditions":175,"interventions":177},"RECRUITING",[60],"2024-11-28",60,[176],"Mastocytosis, Systemic",[41],{"trials":179,"activeCount":146,"soonestReadout":49},[180,188,194],{"nctId":181,"briefTitle":182,"status":183,"phases":184,"conditions":185,"interventions":187},"NCT04714086","Expanded Access Program for Avapritinib","NO_LONGER_AVAILABLE",[],[186],"Solid Tumors",[41],{"nctId":47,"briefTitle":48,"status":171,"phases":189,"primaryCompletion":49,"completion":49,"start":190,"enrollment":191,"conditions":192,"interventions":193},[],"2025-12-09",80,[15],[41],{"nctId":195,"briefTitle":196,"status":197,"phases":198,"conditions":199,"interventions":200},"NCT03862885","Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST","APPROVED_FOR_MARKETING",[],[82],[41],{"intervention":54,"totalTrials":9,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":219,"PHASE3":221,"PHASE4":230,"NA":232},{"trials":204,"activeCount":68},[],{"trials":206,"activeCount":68},[207],{"nctId":208,"briefTitle":209,"status":74,"phases":210,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":216},"NCT07388511","A Study of Elenestinib in Healthy Adult Female Participants",[57],"2026-04-02","2026-02-05",20,[215],"Healthy Participants",[54,217,218],"Midazolam","Levonorgestrel\u002FEthinyl Estradiol",{"trials":220,"activeCount":68},[],{"trials":222,"activeCount":146,"soonestReadout":53},[223],{"nctId":51,"briefTitle":52,"status":171,"phases":224,"primaryCompletion":53,"completion":53,"start":225,"enrollment":226,"conditions":227,"interventions":229},[58,59],"2021-11-30",534,[15,228],"Smoldering Systemic Mastocytosis",[54],{"trials":231,"activeCount":68},[],{"trials":233,"activeCount":68},[],{"intervention":36,"totalTrials":11,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":249,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":237,"activeCount":68},[],{"trials":239,"activeCount":68},[240],{"nctId":241,"briefTitle":242,"status":74,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"NCT06948032","Study of BLU-808 in Healthy Adult Participants",[57],"2025-01-21","2024-08-07",95,[215],[36,217],{"trials":250,"activeCount":146,"soonestReadout":35},[251,259],{"nctId":33,"briefTitle":34,"status":171,"phases":252,"primaryCompletion":35,"completion":35,"start":253,"enrollment":254,"conditions":255,"interventions":258},[58],"2025-05-28",105,[256,257],"Chronic Inducible Urticaria","Chronic Spontaneous Urticaria",[36],{"nctId":260,"briefTitle":261,"status":74,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT06922448","Study of BLU-808 in Allergic Rhinoconjunctivitis",[58],"2025-09-08","2025-04-14",21,[267],"Allergic Rhinoconjunctivitis",[36],{"trials":270,"activeCount":68},[],{"trials":272,"activeCount":68},[],{"trials":274,"activeCount":68},[],{"intervention":159,"totalTrials":146,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":289,"NA":291},{"trials":278,"activeCount":68},[],{"trials":280,"activeCount":68},[],{"trials":282,"activeCount":68},[],{"trials":284,"activeCount":68},[285],{"nctId":150,"briefTitle":151,"status":74,"phases":286,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":287,"interventions":288},[59],[82],[127,159],{"trials":290,"activeCount":68},[],{"trials":292,"activeCount":68},[],{"intervention":294,"totalTrials":11,"cells":295},"Carboplatin",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":297,"activeCount":68},[],{"trials":299,"activeCount":68},[300,333,352],{"nctId":301,"briefTitle":302,"status":303,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":213,"conditions":307,"interventions":328},"NCT05153408","(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","TERMINATED",[57],"2022-12-09","2022-01-13",[308,18,20,22,24,26,309,28,310,311,30,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327],"Lung Neoplasm","Respiratory Tract Diseases","Bronchial Neoplasms","Adenocarcinoma","Neoplasms by Histologic Type","Neoplasms, Nerve Tissue","EGFR C797S","EGFR C797A","EGFR L858R","EGFR Exon 19 Deletion","EGFR Gene Mutation","EGF-R Positive Non-Small Cell Lung Cancer","EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance","EGFR Activating Mutation","Thoracic Neoplasms","Antineoplastic Agents","Protein Kinase Inhibitors","EGFR C797G","EGFR C797X","Non Small Cell Lung Cancer",[329,330,331,332],"BLU-701","osimertinib","carboplatin","pemetrexed",{"nctId":334,"briefTitle":335,"status":303,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":349},"NCT05241873","(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations",[57],"2024-07-31","2022-03-04",103,[341,18,20,22,24,26,342,28,310,311,30,312,343,344,321,323,345,346,347,348],"Lung Neoplasm Malignant","Respiratory Tract Disease","EGFR Exon 20 Mutation","EGFR Exon 20 Insertion Mutation","Metastatic Lung Cancer","Brain Metastases","EGFR-mutated NSCLC","EGFR Atypical Mutations, Including G719X and L861Q",[350,294,351],"BLU-451","Pemetrexed",{"nctId":353,"briefTitle":354,"status":303,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":369},"NCT05252416","(VELA) Study of BLU-222 in Advanced Solid Tumors",[57],"2025-07-04","2022-04-07",50,[360,361,362,363,364,365,366,367,368],"Advanced Solid Tumors","HR+ Breast Cancer","CCNE1 Amplification","HER2-negative Breast Cancer","Ovarian Cancer","Endometrial Cancer","Gastric Cancer","Esophageal Adenocarcinoma","Carcinosarcoma",[370,294,371,372],"BLU-222","Ribociclib","Fulvestrant",{"trials":374,"activeCount":68},[],{"trials":376,"activeCount":68},[],{"trials":378,"activeCount":68},[],{"trials":380,"activeCount":68},[],{"intervention":217,"totalTrials":11,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":384,"activeCount":68},[],{"trials":386,"activeCount":68},[387,391,395],{"nctId":208,"briefTitle":209,"status":74,"phases":388,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":389,"interventions":390},[57],[215],[54,217,218],{"nctId":72,"briefTitle":73,"status":74,"phases":392,"primaryCompletion":76,"completion":77,"start":78,"enrollment":79,"conditions":393,"interventions":394},[57],[81,82,83,84],[41,86],{"nctId":241,"briefTitle":242,"status":74,"phases":396,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":397,"interventions":398},[57],[215],[36,217],{"trials":400,"activeCount":68},[],{"trials":402,"activeCount":68},[],{"trials":404,"activeCount":68},[],{"trials":406,"activeCount":68},[],{"intervention":330,"totalTrials":9,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":410,"activeCount":68},[],{"trials":412,"activeCount":68},[413,425],{"nctId":414,"briefTitle":415,"status":303,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":423},"NCT04862780","(SYMPHONY) Phase 1\u002F2 Study Targeting EGFR Resistance Mechanisms in NSCLC",[57],"2024-10-07","2021-06-29",177,[421,18,20,22,24,26,342,28,310,311,30,312,313,422,314,316,318,319,317,320,321,324,323,322],"Lung Neoplasms","EGFR T790M",[424,330],"BLU-945",{"nctId":301,"briefTitle":302,"status":303,"phases":426,"primaryCompletion":305,"completion":305,"start":306,"enrollment":213,"conditions":427,"interventions":428},[57],[308,18,20,22,24,26,309,28,310,311,30,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327],[329,330,331,332],{"trials":430,"activeCount":68},[],{"trials":432,"activeCount":68},[],{"trials":434,"activeCount":68},[],{"trials":436,"activeCount":68},[],{"intervention":332,"totalTrials":9,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":440,"activeCount":68},[],{"trials":442,"activeCount":68},[443,447],{"nctId":301,"briefTitle":302,"status":303,"phases":444,"primaryCompletion":305,"completion":305,"start":306,"enrollment":213,"conditions":445,"interventions":446},[57],[308,18,20,22,24,26,309,28,310,311,30,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327],[329,330,331,332],{"nctId":334,"briefTitle":335,"status":303,"phases":448,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":449,"interventions":450},[57],[341,18,20,22,24,26,342,28,310,311,30,312,343,344,321,323,345,346,347,348],[350,294,351],{"trials":452,"activeCount":68},[],{"trials":454,"activeCount":68},[],{"trials":456,"activeCount":68},[],{"trials":458,"activeCount":68},[],{"intervention":424,"totalTrials":146,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":462,"activeCount":68},[],{"trials":464,"activeCount":68},[465],{"nctId":414,"briefTitle":415,"status":303,"phases":466,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":467,"interventions":468},[57],[421,18,20,22,24,26,342,28,310,311,30,312,313,422,314,316,318,319,317,320,321,324,323,322],[424,330],{"trials":470,"activeCount":68},[],{"trials":472,"activeCount":68},[],{"trials":474,"activeCount":68},[],{"trials":476,"activeCount":68},[],{"intervention":329,"totalTrials":146,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":480,"activeCount":68},[],{"trials":482,"activeCount":68},[483],{"nctId":301,"briefTitle":302,"status":303,"phases":484,"primaryCompletion":305,"completion":305,"start":306,"enrollment":213,"conditions":485,"interventions":486},[57],[308,18,20,22,24,26,309,28,310,311,30,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327],[329,330,331,332],{"trials":488,"activeCount":68},[],{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[],{"trials":494,"activeCount":68},[],{"intervention":496,"totalTrials":146,"cells":497},"BLU-782",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":499,"activeCount":68},[],{"trials":501,"activeCount":68},[502],{"nctId":503,"briefTitle":504,"status":74,"phases":505,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT03858075","Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults",[57],"2019-09-11","2019-02-12",108,[510],"Healthy Volunteers",[496,512],"BLU-782 taken with food",{"trials":514,"activeCount":68},[],{"trials":516,"activeCount":68},[],{"trials":518,"activeCount":68},[],{"trials":520,"activeCount":68},[],{"intervention":512,"totalTrials":146,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":524,"activeCount":68},[],{"trials":526,"activeCount":68},[527],{"nctId":503,"briefTitle":504,"status":74,"phases":528,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":529,"interventions":530},[57],[510],[496,512],{"trials":532,"activeCount":68},[],{"trials":534,"activeCount":68},[],{"trials":536,"activeCount":68},[],{"trials":538,"activeCount":68},[],{"intervention":540,"totalTrials":146,"cells":541},"Fisogatinib",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":543,"activeCount":68},[],{"trials":545,"activeCount":68},[546],{"nctId":547,"briefTitle":548,"status":74,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT02508467","A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma",[57],"2021-06-30","2024-02-28","2015-07-31",146,[555],"Hepatocellular Carcinoma (HCC)",[540],{"trials":558,"activeCount":68},[],{"trials":560,"activeCount":68},[],{"trials":562,"activeCount":68},[],{"trials":564,"activeCount":68},[],{"intervention":218,"totalTrials":146,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":568,"activeCount":68},[],{"trials":570,"activeCount":68},[571],{"nctId":208,"briefTitle":209,"status":74,"phases":572,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":573,"interventions":574},[57],[215],[54,217,218],{"trials":576,"activeCount":68},[],{"trials":578,"activeCount":68},[],{"trials":580,"activeCount":68},[],{"trials":582,"activeCount":68},[],{"intervention":350,"totalTrials":146,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":586,"activeCount":68},[],{"trials":588,"activeCount":68},[589],{"nctId":334,"briefTitle":335,"status":303,"phases":590,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":591,"interventions":592},[57],[341,18,20,22,24,26,342,28,310,311,30,312,343,344,321,323,345,346,347,348],[350,294,351],{"trials":594,"activeCount":68},[],{"trials":596,"activeCount":68},[],{"trials":598,"activeCount":68},[],{"trials":600,"activeCount":68},[],{"intervention":370,"totalTrials":146,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":617},{"trials":604,"activeCount":68},[],{"trials":606,"activeCount":68},[607],{"nctId":353,"briefTitle":354,"status":303,"phases":608,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":609,"interventions":610},[57],[360,361,362,363,364,365,366,367,368],[370,294,371,372],{"trials":612,"activeCount":68},[],{"trials":614,"activeCount":68},[],{"trials":616,"activeCount":68},[],{"trials":618,"activeCount":68},[],{"intervention":371,"totalTrials":146,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":622,"activeCount":68},[],{"trials":624,"activeCount":68},[625],{"nctId":353,"briefTitle":354,"status":303,"phases":626,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":627,"interventions":628},[57],[360,361,362,363,364,365,366,367,368],[370,294,371,372],{"trials":630,"activeCount":68},[],{"trials":632,"activeCount":68},[],{"trials":634,"activeCount":68},[],{"trials":636,"activeCount":68},[],{"intervention":372,"totalTrials":146,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":640,"activeCount":68},[],{"trials":642,"activeCount":68},[643],{"nctId":353,"briefTitle":354,"status":303,"phases":644,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":645,"interventions":646},[57],[360,361,362,363,364,365,366,367,368],[370,294,371,372],{"trials":648,"activeCount":68},[],{"trials":650,"activeCount":68},[],{"trials":652,"activeCount":68},[],{"trials":654,"activeCount":68},[],{"intervention":656,"totalTrials":146,"cells":657},"BLU-263",{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":659,"activeCount":68},[],{"trials":661,"activeCount":68},[662],{"nctId":663,"briefTitle":664,"status":303,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT05609942","Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies",[57],"2025-01-14","2025-03-10","2023-09-25",9,[136],[656,672],"Azacitidine",{"trials":674,"activeCount":68},[],{"trials":676,"activeCount":68},[],{"trials":678,"activeCount":68},[],{"trials":680,"activeCount":68},[],{"intervention":672,"totalTrials":146,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":68},[],{"trials":686,"activeCount":68},[687],{"nctId":663,"briefTitle":664,"status":303,"phases":688,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":689,"interventions":690},[57],[136],[656,672],{"trials":692,"activeCount":68},[],{"trials":694,"activeCount":68},[],{"trials":696,"activeCount":68},[],{"trials":698,"activeCount":68},[],{"intervention":700,"totalTrials":146,"cells":701},"pralsetinib",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":703,"activeCount":68},[],{"trials":705,"activeCount":68},[],{"trials":707,"activeCount":68},[],{"trials":709,"activeCount":68},[],{"trials":711,"activeCount":68},[],{"trials":713,"activeCount":68},[714],{"nctId":715,"briefTitle":716,"status":197,"phases":717,"conditions":718,"interventions":721},"NCT04204928","Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC",[],[719,720],"Non-Small Cell Lung Cancer","Medullary Thyroid Cancer",[700]]